REFERENCES
1. North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res. 2012;110:1097-108.
2. Ungvari Z, Tarantini S, Donato AJ, Galvan V, Csiszar A. Mechanisms of vascular aging. Circ Res. 2018;123:849-67.
4. Tanriover C, Copur S, Mutlu A, et al. Early aging and premature vascular aging in chronic kidney disease. Clin Kidney J. 2023;16:1751-65.
5. Fountoulakis N, Miyamoto Y, Pavkov ME, Karalliedde J, Maltese G. Pathophysiology of vascular ageing and the effect of novel cardio-renal protective medications in preventing progression of chronic kidney disease in people living with diabetes. Diabet Med. 2025;42:e15464.
6. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010;121:505-11.
7. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318-27.
8. Montagne A, Barnes SR, Sweeney MD, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015;85:296-302.
9. Sabbatinelli J, Prattichizzo F, Olivieri F, Procopio AD, Rippo MR, Giuliani A. Where metabolism meets senescence: focus on endothelial cells. Front Physiol. 2019;10:1523.
10. Pacinella G, Ciaccio AM, Tuttolomondo A. Endothelial dysfunction and chronic inflammation: the cornerstones of vascular alterations in age-related diseases. Int J Mol Sci. 2022;23:15722.
11. Lacolley P, Regnault V, Segers P, Laurent S. Vascular Smooth Muscle Cells and Arterial Stiffening: Relevance in Development, Aging, and Disease. Physiol Rev. 2017;97:1555-617.
12. Ungvari Z, Tarantini S, Kiss T, et al. Endothelial dysfunction and angiogenesis impairment in the ageing vasculature. Nat Rev Cardiol. 2018;15:555-65.
13. Oh HS, Rutledge J, Nachun D, et al. Organ aging signatures in the plasma proteome track health and disease. Nature. 2023;624:164-72.
14. Pilling LC, Atkins JL, Bowman K, et al. Human longevity is influenced by many genetic variants: evidence from 75,000 UK Biobank participants. Aging. 2016;8:547-60.
15. Grosse L, Wagner N, Emelyanov A, et al. Defined p16(High) senescent cell types are indispensable for mouse healthspan. Cell Metab. 2020;32:87-99.e6.
16. Kalucka J, de Rooij LPMH, Goveia J, et al. Single-cell transcriptome atlas of murine endothelial cells. Cell. 2020;180:764-779.e20.
17. Gulej R, Nyúl-Tóth Á, Csik B, et al. Rejuvenation of cerebromicrovascular function in aged mice through heterochronic parabiosis: insights into neurovascular coupling and the impact of young blood factors. Geroscience. 2024;46:327-47.
18. Loffredo FS, Steinhauser ML, Jay SM, et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell. 2013;153:828-39.
19. Villeda SA, Luo J, Mosher KI, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477:90-4.
20. Chen X, Luo Y, Zhu Q, et al. Small extracellular vesicles from young plasma reverse age-related functional declines by improving mitochondrial energy metabolism. Nat Aging. 2024;4:814-38.
21. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the cardiovascular health study. Circulation. 2007;115:2390-7.
22. Tian YE, Cropley V, Maier AB, Lautenschlager NT, Breakspear M, Zalesky A. Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality. Nat Med. 2023;29:1221-31.
23. Donato AJ, Machin DR, Lesniewski LA. Mechanisms of dysfunction in the aging vasculature and role in age-related disease. Circ Res. 2018;123:825-48.
24. Wang M, Kim SH, Monticone RE, Lakatta EG. Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis. Hypertension. 2015;65:698-703.
25. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14:576-90.
26. Mayer O, Gelžinský J, Seidlerová J, et al. The role of advanced glycation end products in vascular aging: which parameter is the most suitable as a biomarker? J Hum Hypertens. 2021;35:240-9.
27. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15:104-16.
28. Mencke R, Hillebrands JL. ; NIGRAM consortium. The role of the anti-ageing protein Klotho in vascular physiology and pathophysiology. Ageing Res Rev. 2017;35:124-46.
29. Toth L, Czigler A, Hegedus E, et al. Age-related decline in circulating IGF-1 associates with impaired neurovascular coupling responses in older adults. Geroscience. 2022;44:2771-83.
30. Childs BG, Li H, van Deursen JM. Senescent cells: a therapeutic target for cardiovascular disease. J Clin Invest. 2018;128:1217-28.
31. Ghebre YT, Yakubov E, Wong WT, et al. Vascular aging: implications for cardiovascular disease and therapy. Transl Med. 2016;6:183.
32. Jones RC, Karkanias J, Krasnow MA, et al. ; Tabula Sapiens Consortium*. The tabula sapiens: a multiple-organ, single-cell transcriptomic atlas of humans. Science. 2022;376:eabl4896.
33. Rivera CF, Farra YM, Silvestro M, et al. Mapping the unicellular transcriptome of the ascending thoracic aorta to changes in mechanosensing and mechanoadaptation during aging. Aging Cell. 2024;23:e14197.
34. Li Y, Ren P, Dawson A, et al. Single-cell transcriptome analysis reveals dynamic cell populations and differential gene expression patterns in control and aneurysmal human aortic tissue. Circulation. 2020;142:1374-88.
35. Cheng J, Wu H, Xie C, et al. Single-cell mapping of large and small arteries during hypertensive aging. J Gerontol A Biol Sci Med Sci. 2024;79:glad188.
36. Kim SY, Cheon J. Senescence-associated microvascular endothelial dysfunction: a focus on the blood-brain and blood-retinal barriers. Ageing Res Rev. 2024;100:102446.
37. Fu X, Zhao Y, Cui X, et al. Cxcl9 modulates aging associated microvascular metabolic and angiogenic dysfunctions in subcutaneous adipose tissue. Angiogenesis. 2025;28:17.
38. Dobner S, Tóth F, de Rooij LPMH. A high-resolution view of the heterogeneous aging endothelium. Angiogenesis. 2024;27:129-45.
39. Liu Z, Huang Y, Wang D, et al. Insights gained from single-cell RNA analysis of murine endothelial cells in aging hearts. Heliyon. 2023;9:e18324.
40. Gao P, Gao P, Choi M, et al. Transcriptome analysis of mouse aortae reveals multiple novel pathways regulated by aging. Aging. 2020;12:15603-23.
41. Iwao T, Takata F, Matsumoto J, et al. Senescence in brain pericytes attenuates blood-brain barrier function in vitro: A comparison of serially passaged and isolated pericytes from aged rat brains. Biochem Biophys Res Commun. 2023;645:154-63.
42. Berthiaume AA, Schmid F, Stamenkovic S, et al. Pericyte remodeling is deficient in the aged brain and contributes to impaired capillary flow and structure. Nat Commun. 2022;13:5912.
43. Dulauroy S, Di Carlo SE, Langa F, Eberl G, Peduto L. Lineage tracing and genetic ablation of ADAM12+ perivascular cells identify a major source of profibrotic cells during acute tissue injury. Nat Med. 2012;18:1262-70.
44. Dias Moura Prazeres PH, Sena IFG, Borges IDT, et al. Pericytes are heterogeneous in their origin within the same tissue. Dev Biol. 2017;427:6-11.
45. Yamazaki T, Nalbandian A, Uchida Y, et al. Tissue myeloid progenitors differentiate into pericytes through TGF-β signaling in developing skin vasculature. Cell Rep. 2017;18:2991-3004.
46. Armulik A, Genové G, Mäe M, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468:557-61.
47. Greenberg JI, Shields DJ, Barillas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008;456:809-13.
48. Jiang L, Xu L, Mao J, et al. Rheb/mTORC1 signaling promotes kidney fibroblast activation and fibrosis. J Am Soc Nephrol. 2013;24:1114-26.
49. Bennett HC, Zhang Q, Wu YT, et al. Aging drives cerebrovascular network remodeling and functional changes in the mouse brain. Nat Commun. 2024;15:6398.
50. Shaito A, Aramouni K, Assaf R, et al. Oxidative stress-induced endothelial dysfunction in cardiovascular diseases. Front Biosci. 2022;27:105.
51. Hernandez-Navarro I, Botana L, Diez-Mata J, et al. Replicative endothelial cell senescence may lead to endothelial dysfunction by increasing the BH2/BH4 ratio induced by oxidative stress, reducing BH4 availability, and decreasing the expression of eNOS. Int J Mol Sci. 2024;25:9890.
52. Bouly M, Bourguignon MP, Roesch S, et al. Aging increases circulating BH2 without modifying BH4 levels and impairs peripheral vascular function in healthy adults. Transl Res. 2021;238:36-48.
53. Chuaiphichai S, Rashbrook VS, Hale AB, et al. Endothelial cell tetrahydrobiopterin modulates sensitivity to ang (angiotensin) ii-induced vascular remodeling, blood pressure, and abdominal aortic aneurysm. Hypertension. 2018;72:128-38.
54. Bisconti AV, Garten RS, Broxterman RM, et al. No effect of acute tetrahydrobiopterin (BH4) supplementation on vascular dysfunction in the old. J Appl Physiol. 2022;132:773-84.
55. Lin H, Pan J, Zhang J, et al. Intermedin protects peritubular capillaries by inhibiting eNOS uncoupling through AMPK/GTPCH-I/BH4 pathway and alleviate CKD following AKI. Free Radical Biol Med. 2025;234:72-85.
56. Du J, Zhu X, Zhang Y, et al. CTRP13 attenuates atherosclerosis by inhibiting endothelial cell ferroptosis via activating GCH1. Int Immunopharmacol. 2024;143:113617.
57. Rodríguez C, Muñoz M, Contreras C, Prieto D. AMPK, metabolism, and vascular function. FEBS J. 2021;288:3746-71.
58. Chang TT, Lin LY, Chen C, Chen JW. CCL4 contributes to aging related angiogenic insufficiency through activating oxidative stress and endothelial inflammation. Angiogenesis. 2024;27:475-99.
59. Yang Y, Chen H, Liu Q, Niu Y, Mao C, Wang R. Elucidating molecular pathogenesis and developing targeted therapeutic interventions for cerebrovascular endothelial cell-mediated vascular dementia. Front Aging Neurosci. 2025;17:1623050.
60. Li J, Wang Y, Shrestha S, Gewirtz AT, Ding Y, Zou J. Targeting Gut Microbiota to Combat Vascular Aging and Cardiovascular Disease: Mechanisms and Therapeutic Potential. Nutrients. 2025;17:2887.
61. Madeddu P, Goulopoulou S, Wambeke D. Integrating endothelial-derived hyperpolarizing signaling into a multitarget therapeutic strategy for microvascular disease. arXiv 2025;arXiv:2508.01618. Available from https://arxiv.org/abs/2508.01618 [accessed 2 March 2026].
62. Shi SM, Suh RJ, Shon DJ, et al. Glycocalyx dysregulation impairs blood-brain barrier in ageing and disease. Nature. 2025;639:985-94.
63. Milusev A, Rieben R, Sorvillo N. The Endothelial glycocalyx: a possible therapeutic target in cardiovascular disorders. Front Cardiovasc Med. 2022;9:897087.
64. Ying J, Zhang C, Wang Y, et al. Sulodexide improves vascular permeability via glycocalyx remodelling in endothelial cells during sepsis. Front Immunol. 2023;14:1172892.
65. Charfeddine S, Ibnhadjamor H, Jdidi J, et al. Sulodexide significantly improves endothelial dysfunction and alleviates chest pain and palpitations in patients with long-COVID-19: insights from TUN-EndCOV study. Front Cardiovasc Med. 2022;9:866113.
66. Pollmann S, Scharnetzki D, Manikowski D, Lenders M, Brand E. Endothelial dysfunction in Fabry disease is related to glycocalyx degradation. Front Immunol. 2021;12:789142.
67. Mishra S, Ipe U, Nottebaum AF, Peters KG, Vestweber D. Inhibition of VE-PTP rejuvenates Schlemm’s canal in aged mice and acts via Tie2. PLoS ONE. 2025;20:e0323615.
68. Zeng Y, Adamson RH, Curry FR, Tarbell JM. Sphingosine-1-phosphate protects endothelial glycocalyx by inhibiting syndecan-1 shedding. Am J Physiol Heart Circ Physiol. 2014;306:H363-72.
69. Souilhol C, Serbanovic-Canic J, Fragiadaki M, et al. Endothelial responses to shear stress in atherosclerosis: a novel role for developmental genes. Nat Rev Cardiol. 2020;17:52-63.
70. Wang X, Shen Y, Shang M, Liu X, Munn LL. Endothelial mechanobiology in atherosclerosis. Cardiovasc Res. 2023;119:1656-75.
71. Zheng Q, Zou Y, Teng P, et al. Mechanosensitive channel PIEZO1 senses shear force to induce KLF2/4 expression via CaMKII/MEKK3/ERK5 axis in endothelial cells. Cells. 2022;11:2191.
72. Dabravolski SA, Sukhorukov VN, Kalmykov VA, Grechko AV, Shakhpazyan NK, Orekhov AN. The role of KLF2 in the regulation of atherosclerosis development and potential use of KLF2-targeted therapy. Biomedicines. 2022;10:254.
73. Joshi D, Coon BG, Chakraborty R, et al. Endothelial γ-protocadherins inhibit KLF2 and KLF4 to promote atherosclerosis. Nat Cardiovasc Res. 2024;3:1035-48.
74. Barettino A, González-Gómez C, Gonzalo P, et al. Endothelial YAP/TAZ activation promotes atherosclerosis in a mouse model of Hutchinson-Gilford progeria syndrome. J Clin Invest. 2024;134:e173448.
75. Santana Nunez D, Malik AB, Lee Q, et al. Piezo1 induces endothelial responses to shear stress via soluble adenylyl cyclase-IP3R2 circuit. iScience. 2023;26:106661.
76. Yang Y, Wang D, Zhang C, et al. Piezo1 mediates endothelial atherogenic inflammatory responses via regulation of YAP/TAZ activation. Hum Cell. 2022;35:51-62.
77. Sun L, Wang L, Ye KX, et al. Endothelial glycocalyx in aging and age-related diseases. Aging Dis. 2023;14:1606-17.
78. Syeda R, Xu J, Dubin AE, et al. Chemical activation of the mechanotransduction channel Piezo1. Elife. 2015;4:e07369.
79. Wijerathne TD, Ozkan AD, Lacroix JJ. Yoda1’s energetic footprint on Piezo1 channels and its modulation by voltage and temperature. Proc Natl Acad Sci U S A. 2022;119:e2202269119.
80. Matrongolo MJ, Ang PS, Wu J, et al. Piezo1 agonist restores meningeal lymphatic vessels, drainage, and brain-CSF perfusion in craniosynostosis and aged mice. J Clin Invest. 2023;134:e171468.
81. Müller L, Di Benedetto S. Inflammaging, immunosenescence, and cardiovascular aging: insights into long COVID implications. Front Cardiovasc Med. 2024;11:1384996.
82. Kumar M, Yan P, Kuchel GA, Xu M. Cellular senescence as a targetable risk factor for cardiovascular diseases: therapeutic implications: JACC Family Series. JACC Basic Transl Sci. 2024;9:522-34.
83. Ueda K, Sakai C, Ishida T, et al. Cigarette smoke induces mitochondrial DNA damage and activates cGAS-STING pathway: application to a biomarker for atherosclerosis. Clin Sci. 2023;137:163-80.
84. Brunt VE, Gioscia-Ryan RA, Casso AG, et al. Trimethylamine-N-oxide promotes age-related vascular oxidative stress and endothelial dysfunction in mice and healthy humans. Hypertension. 2020;76:101-12.
85. Longtine AG, Greenberg NT, Bernaldo de Quirós Y, Brunt VE. The gut microbiome as a modulator of arterial function and age-related arterial dysfunction. Am J Physiol Heart Circ Physiol. 2024;326:H986-H1005.
86. Díez-Díez M, Ramos-Neble BL, de la Barrera J, et al. Unidirectional association of clonal hematopoiesis with atherosclerosis development. Nat Med. 2024;30:2857-66.
87. Oren O, Small AM, Libby P. Clonal hematopoiesis and atherosclerosis. J Clin Invest. 2024;134:e180066.
88. Rauch PJ, Gopakumar J, Silver AJ, et al. Loss-of-function mutations in Dnmt3a and Tet2lead to accelerated atherosclerosis and concordant macrophage phenotypes. Nat Cardiovasc Res. 2023;2:805-18.
89. Zuriaga MA, Yu Z, Matesanz N, et al. Colchicine prevents accelerated atherosclerosis in TET2-mutant clonal haematopoiesis. Eur Heart J. 2024;45:4601-15.
90. Everett BM, MacFadyen JG, Thuren T, Libby P, Glynn RJ, Ridker PM. Inhibition of interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS Trial. J Am Coll Cardiol. 2020;76:1660-70.
91. von Scheidt M, Adkar SS, Krefting J, et al. Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease. Eur Heart J. 2026;47:453-69.
92. FDA approval letter for Lodoco (colchicine) 0.5 mg (June 16, 2023); ACC perspective on the evolving role of colchicine (2025) Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/215727Orig1s000ltr.pdf [Last accessed on 12 Mar 2026].
93. Zhang Z, Zhao X, Zhang X, et al. Mitochondrial cardiovascular diseases: molecular mechanisms, multi-omics exploration and therapeutic strategies. J Adv Res. 2025.
94. Lin JR, Shen WL, Yan C, Gao PJ. Downregulation of dynamin-related protein 1 contributes to impaired autophagic flux and angiogenic function in senescent endothelial cells. Arterioscler Thromb Vasc Biol. 2015;35:1413-22.
95. Janaszak-Jasiecka A, Płoska A, Wierońska JM, Dobrucki LW, Kalinowski L. Endothelial dysfunction due to eNOS uncoupling: molecular mechanisms as potential therapeutic targets. Cell Mol Biol Lett. 2023;28:21.
96. Rossman MJ, Santos-Parker JR, Steward CAC, et al. Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults. Hypertension. 2018;71:1056-63.
97. Gioscia-Ryan RA, LaRocca TJ, Sindler AL, Zigler MC, Murphy MP, Seals DR. Mitochondria-targeted antioxidant (MitoQ) ameliorates age-related arterial endothelial dysfunction in mice. J Physiol. 2014;592:2549-61.
98. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372:1224-9.
99. Fang EF, Hou Y, Lautrup S, et al. NAD+ augmentation restores mitophagy and limits accelerated aging in Werner syndrome. Nat Commun. 2019;10:5284.
100. Chen R, McVey DG, Shen D, Huang X, Ye S. Phenotypic switching of vascular smooth muscle cells in atherosclerosis. J Am Heart Assoc. 2023;12:e031121.
101. Gong X, Liu Y, Liu H, et al. Re-analysis of single-cell transcriptomics reveals a critical role of macrophage-like smooth muscle cells in advanced atherosclerotic plaque. Theranostics. 2024;14:1450-63.
102. Li Y, Jie W, Qi Y, et al. Inhibition of RIPK1 alleviating vascular smooth muscle cells osteogenic transdifferentiation via Runx2. iScience. 2024;27:108766.
103. Jafarinia H, Khalilimeybodi A, Barrasa-Fano J, Fraley SI, Rangamani P, Carlier A. Insights gained from computational modeling of YAP/TAZ signaling for cellular mechanotransduction. NPJ Syst Biol Appl. 2024;10:90.
104. Ritsvall O, Albinsson S. Emerging role of YAP/TAZ in vascular mechanotransduction and disease. Microcirculation. 2024;31:e12838.
105. He D, Ma J, Zhou Z, et al. TET2 suppresses vascular calcification by forming an inhibitory complex with HDAC1/2 and SNIP1 independent of demethylation. J Clin Invest. 2025;135:e186673.
106. Li L, Cheng M, Jin J, et al. The m6A reader YTHDF2 protects vascular smooth muscle cells against the osteogenic differentiation through targeting Runx2. Renal Fail. 2025;47:2488876.
107. Herzog MJ, Müller P, Lechner K, et al. Arterial stiffness and vascular aging: mechanisms, prevention, and therapy. Signal Transduct Target Ther. 2025;10:282.
108. Lambert J, Jørgensen HF. Epigenetic regulation of vascular smooth muscle cell phenotypes in atherosclerosis. Atherosclerosis. 2025;401:119085.
109. Zhu C, Bishop T, Gregorich ZR, Guo W. Titin is a new factor regulating arterial stiffness through vascular smooth muscle cell tone in male rats. Physiol Rep. 2025;13:e70270.
110. Kaistha A, Oc S, Garrido AM, et al. Premature cell senescence promotes vascular smooth muscle cell phenotypic modulation and resistance to re-differentiation. Cardiovasc Res. 2025;121:1448-63.
111. Azar P, Jarr KU, Gomez D, Jørgensen HF, Leeper NJ, Bochaton-Piallat ML. Smooth muscle cells in atherosclerosis: essential but overlooked translational perspectives. Eur Heart J. 2025;46:4862-75.
112. Gadecka A, Nowak N, Bulanda E, et al. The senolytic cocktail, dasatinib and quercetin, impacts the chromatin structure of both young and senescent vascular smooth muscle cells. Geroscience. 2025;47:3907-25.
113. Rad AN, Grillari J. Current senolytics: mode of action, efficacy and limitations, and their future. Mech Ageing Dev. 2024;217:111888.
114. Zha Y, Zhuang W, Yang Y, Zhou Y, Li H, Liang J. Senescence in vascular smooth muscle cells and atherosclerosis. Front Cardiovasc Med. 2022;9:910580.
115. Cheng M, Jin J, Zhang D, et al. METTL3 obstructs vascular smooth muscle cells osteogenic reprogramming by methylating Runx2 in chronic kidney disease. Commun Biol. 2025;8:582.
116. Chen A, Yuan P, Lu Y, et al. Smooth muscle-specific HuR knockout attenuates vascular calcification. J Mol Cell Cardiol. 2025;205:117-28.
117. Bloom SI, Islam MT, Lesniewski LA, Donato AJ. Mechanisms and consequences of endothelial cell senescence. Nat Rev Cardiol. 2023;20:38-51.
118. Culley MK, Chan SY. Endothelial senescence: a new age in pulmonary hypertension. Circ Res. 2022;130:928-41.
119. van der Linden J, Stefens SJM, Heredia-Genestar JM, et al. Ercc1 DNA repair deficiency results in vascular aging characterized by VSMC phenotype switching, ECM remodeling, and an increased stress response. Aging Cell. 2024;23:e14126.
120. Stefens SJM, van Vliet N, IJpma A, et al. Increased vascular smooth muscle cell senescence in aneurysmal Fibulin-4 mutant mice. NPJ Aging. 2024;10:31.
121. Bloom SI, Liu Y, Tucker JR, et al. Endothelial cell telomere dysfunction induces senescence and results in vascular and metabolic impairments. Aging Cell. 2023;22:e13875.
122. Gao Z, Santos RB, Rupert J, et al. Endothelial-specific telomerase inactivation causes telomere-independent cell senescence and multi-organ dysfunction characteristic of aging. Aging Cell. 2024;23:e14138.
123. Chen Y, Liang L, Wu C, et al. Epigenetic control of vascular smooth muscle cell function in atherosclerosis: a role for DNA methylation. DNA Cell Biol. 2022;41:824-37.
124. Wang K, Liu H, Hu Q, et al. Epigenetic regulation of aging: implications for interventions of aging and diseases. Signal Transduct Target Ther. 2022;7:374.
125. Han Y, Kim SY. Endothelial senescence in vascular diseases: current understanding and future opportunities in senotherapeutics. Exp Mol Med. 2023;55:1-12.
126. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554-63.
127. Nambiar A, Kellogg D 3rd, Justice J, et al. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability. EBioMedicine. 2023;90:104481.
128. Gonzales MM, Garbarino VR, Kautz TF, et al. Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial. Nat Med. 2023;29:2481-8.
129. Zhu X, Zhang C, Liu L, Xu L, Yao L. Senolytic combination of dasatinib and quercetin protects against diabetic kidney disease by activating autophagy to alleviate podocyte dedifferentiation via the Notch pathway. Int J Mol Med. 2024;53:26.
130. Atlante S, Gottardi Zamperla M, Cis L, Farsetti A, Gaetano C. Senolytic therapies for cardiovascular aging: tackling fibrosis and metabolic dysfunction. Eur J Intern Med. 2025;140:106413.
131. Yang B, Li T, Wang Z, et al. Ruxolitinib-based senomorphic therapy mitigates cardiomyocyte senescence in septic cardiomyopathy by inhibiting the JAK2/STAT3 signaling pathway. Int J Biol Sci. 2024;20:4314-40.
132. Lelarge V, Capelle R, Oger F, Mathieu T, Le Calvé B. Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients’ treatment. NPJ Aging. 2024;10:12.
133. Tai S, Sun J, Zhou Y, et al. Metformin suppresses vascular smooth muscle cell senescence by promoting autophagic flux. J Adv Res. 2022;41:205-18.
134. Wang B, Jiang T, Qi Y, et al. AGE-RAGE axis and cardiovascular diseases: pathophysiologic mechanisms and prospects for clinical applications. Cardiovasc Drugs Ther. 2025;39:1489-506.
135. Castro MM, Rizzi E, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol. 2010;29:194-201.
136. Krishnan S, Suarez-Martinez AD, Bagher P, et al. Microvascular dysfunction and kidney disease: challenges and opportunities? Microcirculation. 2021;28:e12661.
137. Hanssen H, Streese L, Vilser W. Retinal vessel diameters and function in cardiovascular risk and disease. Prog Retin Eye Res. 2022;91:101095.
138. Rensma SP, Stehouwer CDA, Van Boxtel MPJ, et al. Associations of arterial stiffness with cognitive performance, and the role of microvascular dysfunction: the maastricht study. Hypertension. 2020;75:1607-14.
139. Sladitschek-Martens HL, Guarnieri A, Brumana G, et al. YAP/TAZ activity in stromal cells prevents ageing by controlling cGAS-STING. Nature. 2022;607:790-8.
140. Zhang L, Xia C, Yang Y, et al. DNA methylation and histone post-translational modifications in atherosclerosis and a novel perspective for epigenetic therapy. Cell Commun Signal. 2023;21:344.
141. Grootaert MOJ, Finigan A, Figg NL, Uryga AK, Bennett MR. SIRT6 protects smooth muscle cells from senescence and reduces atherosclerosis. Circ Res. 2021;128:474-91.
142. Li X, Chen M, Chen X, et al. TRAP1 drives smooth muscle cell senescence and promotes atherosclerosis via HDAC3-primed histone H4 lysine 12 lactylation. Eur Heart J. 2024;45:4219-35.
143. Dong M, Zhang Y, Chen M, et al. ASF1A-dependent P300-mediated histone H3 lysine 18 lactylation promotes atherosclerosis by regulating EndMT. Acta Pharm Sin B. 2024;14:3027-48.
144. Pan Y, Zhang Q, Li C, et al. SIRT5 alleviates apoptosis of vascular endothelial cells under simulated microgravity via desuccinylation of ERO1A. Int J Mol Sci. 2025;26:2908.
145. Hua CC, Liu XM, Liang LR, Wang LF, Zhong JC. Targeting the microRNA-34a as a novel therapeutic strategy for cardiovascular diseases. Front Cardiovasc Med. 2021;8:784044.
146. Qian Z, Huang Y, Yang N, et al. miR-34a-5p/MARCHF8/ADAM10 axis in the regulation of vascular endothelial cell dysfunction and senescence. Mech Ageing Dev. 2025;225:112060.
147. Ardinal AP, Wiyono AV, Estiko RI. Unveiling the therapeutic potential of miR-146a: targeting innate inflammation in atherosclerosis. J Cell Mol Med. 2024;28:e70121.
148. Zhai K, Deng L, Wu Y, et al. Extracellular vesicle-derived miR-146a as a novel crosstalk mechanism for high-fat induced atherosclerosis by targeting SMAD4. J Adv Res. 2025;73:729-41.
149. Guo B, Gu J, Zhuang T, et al. MicroRNA-126: from biology to therapeutics. Biomed Pharmacother. 2025;185:117953.
150. Ye ZQ, Meng XH, Fang X, Liu HY, Mwindadi HH. MiR-126 regulates the effect of mesenchymal stem cell vascular repair on carotid atherosclerosis through MAPK/ERK signaling pathway. World J Stem Cells. 2025;17:106520.
151. Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and back. Physiol Rev. 2019;99:21-78.
152. Graves SI, Baker DJ. Implicating endothelial cell senescence to dysfunction in the ageing and diseased brain. Basic Clin Pharmacol Toxicol. 2020;127:102-10.
153. Gorelick PB, Scuteri A, Black SE, et al. ; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42:2672-713.
154. Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14:133-50.
155. Nation DA, Sweeney MD, Montagne A, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25:270-6.
156. Montagne A, Zhao Z, Zlokovic BV. Alzheimer’s disease: a matter of blood-brain barrier dysfunction? J Exp Med. 2017;214:3151-69.
158. Ma S, Xie X, Yuan R, et al. Vascular aging and atherosclerosis: a perspective on aging. Aging Dis. 2024;16:33-48.
159. Kirkman DL, Robinson AT, Rossman MJ, Seals DR, Edwards DG. Mitochondrial contributions to vascular endothelial dysfunction, arterial stiffness, and cardiovascular diseases. Am J Physiol Heart Circ Physiol. 2021;320:H2080-100.
160. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-71.
161. Chirinos JA, Segers P, Hughes T, Townsend R. Large-artery stiffness in health and disease: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74:1237-63.
162. Chirinos JA, Segers P. Noninvasive evaluation of left ventricular afterload: part 2: arterial pressure-flow and pressure-volume relations in humans. Hypertension. 2010;56:563-70.
163. Coutinho T, Mielniczuk LM, Srivaratharajah K, deKemp R, Wells GA, Beanlands RS. Coronary artery microvascular dysfunction: role of sex and arterial load. Int J Cardiol. 2018;270:42-7.
164. Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat Rev Cardiol. 2021;18:58-68.
165. Laurent S, Cockcroft J, Van Bortel L, et al. ; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588-605.
166. Vishram-Nielsen JKK, Laurent S, Nilsson PM, et al. ; MORGAM Project. Does estimated pulse wave velocity add prognostic information? MORGAM prospective cohort project. Hypertension. 2020;75:1420-8.
167. Ejiri K, Ding N, Kim E, et al. Association of segment-specific pulse wave velocity with vascular calcification: the ARIC (atherosclerosis risk in communities) study. J Am Heart Assoc. 2024;13:e031778.
168. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340:14-22.
169. Tanaka T, Basisty N, Fantoni G, et al. Plasma proteomic biomarker signature of age predicts health and life span. Elife. 2020;9:e61073.
170. Shah AM, Myhre PL, Arthur V, et al. Large scale plasma proteomics identifies novel proteins and protein networks associated with heart failure development. Nat Commun. 2024;15:528.
171. Soto-Rojas LO, Pacheco-Herrero M, Martínez-Gómez PA, et al. The neurovascular unit dysfunction in Alzheimer’s disease. Int J Mol Sci. 2021;22:2022.
172. Vanlandewijck M, He L, Mäe MA, et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature. 2018;554:475-80.
173. Nikolakopoulou AM, Montagne A, Kisler K, et al. Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss. Nat Neurosci. 2019;22:1089-98.
174. Yamamoto K, Nogimori Y, Imamura H, Ando J. Shear stress activates mitochondrial oxidative phosphorylation by reducing plasma membrane cholesterol in vascular endothelial cells. Proc Natl Acad Sci U S A. 2020;117:33660-7.
175. Nehra G, Bauer B, Hartz AMS. Blood-brain barrier leakage in Alzheimer’s disease: from discovery to clinical relevance. Pharmacol Ther. 2022;234:108119.
176. Montagne A, Barnes SR, Nation DA, Kisler K, Toga AW, Zlokovic BV. Imaging subtle leaks in the blood-brain barrier in the aging human brain: potential pitfalls, challenges, and possible solutions. Geroscience. 2022;44:1339-51.
177. Jefferson AL, Cambronero FE, Liu D, et al. Higher aortic stiffness is related to lower cerebral blood flow and preserved cerebrovascular reactivity in older adults. Circulation. 2018;138:1951-62.
178. Tomoto T, Tarumi T, Zhang R. Central arterial stiffness, brain white matter hyperintensity and total brain volume across the adult lifespan. J Hypertens. 2023;41:819-29.
179. Aimagambetova B, Ariko T, Merritt S, Rundek T. Arterial stiffness measured by pulse wave velocity correlated with cognitive decline in hypertensive individuals: a systematic review. BMC Neurol. 2024;24:393.
180. Wang W, Norby FL, George KM, et al. Association of carotid intima-media thickness and other carotid ultrasound features with incident dementia in the ARIC-NCS. J Am Heart Assoc. 2021;10:e020489.
181. Geijselaers SL, Sep SJ, Schram MT, et al. Carotid stiffness is associated with impairment of cognitive performance in individuals with and without type 2 diabetes. The Maastricht study. Atherosclerosis. 2016;253:186-93.
182. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension. 2005;46:200-4.
183. Sedaghat S, Mattace-Raso FU, Hoorn EJ, et al. Arterial stiffness and decline in kidney function. Clin J Am Soc Nephrol. 2015;10:2190-7.
184. Daehn IS, Duffield JS. The glomerular filtration barrier: a structural target for novel kidney therapies. Nat Rev Drug Discov. 2021;20:770-88.
185. Yao Z, Ishigami J, Kim E, et al. Arterial stiffness and subsequent incidence of CKD and Kidney function decline in a large longitudinal community cohort: the atherosclerosis in communities (ARIC) study. Am J Kidney Dis. 2025;86:32-42.
186. Liu JJ, Liu S, Lee J, et al. Aortic pulse wave velocity, central pulse pressure, augmentation index and chronic kidney disease progression in individuals with type 2 diabetes: a 3- year prospective study. BMC Nephrol. 2020;21:359.
187. Nagayama D, Fujishiro K, Miyoshi T, et al. Predictive ability of arterial stiffness parameters for renal function decline: a retrospective cohort study comparing cardio-ankle vascular index, pulse wave velocity and cardio-ankle vascular index 0. J Hypertens. 2022;40:1294-302.
188. Grams ME, Surapaneni A, Chen J, et al. Proteins associated with risk of kidney function decline in the general population. J Am Soc Nephrol. 2021;32:2291-302.
189. Li Y, Liu Y, Liu S, et al. Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. Signal Transduct Target Ther. 2023;8:152.
190. Chaudhuri J, Bains Y, Guha S, et al. The role of advanced glycation end products in aging and metabolic diseases: bridging association and causality. Cell Metab. 2018;28:337-52.
191. Franceković P, Gliemann L. Endothelial glycocalyx preservation-impact of nutrition and lifestyle. Nutrients. 2023;15:2573.
192. Banerjee S, Mwangi JG, Stanley TK, Mitra R, Ebong EE. Regeneration and assessment of the endothelial glycocalyx to address cardiovascular disease. Ind Eng Chem Res. 2021;60:17328-47.
193. Wang J, Ma L, Fang Y, Ye T, Li H, Lan P. Factors influencing glycocalyx degradation: a narrative review. Front Immunol. 2024;15:1490395.
194. Gimblet CJ, Ernst JW, Bell B, et al. Effect of glycocalyx-targeted therapy on vascular function in older adults: a randomized controlled trial. J Appl Physiol. 2024;136:1488-95.
195. Smith JA, Ramirez-Perez FI, Burr K, et al. Impact of dietary supplementation of glycocalyx precursors on vascular function in type 2 diabetes. J Appl Physiol. 2024;137:1592-603.
196. ClinicalTrials.gov. Targeting the endothelial glycocalyx to enhance vascular function and exercise-induced vascular adaptations in type 2 diabetes. Available from: https://clinicaltrials.gov/study/NCT05205005 [Last accessed on 12 Mar 2026].
197. Mitra R, Pentland K, Kolev S, et al. Co-therapy with S1P and heparan sulfate derivatives to restore endothelial glycocalyx and combat pro-atherosclerotic endothelial dysfunction. Life Sci. 2025;377:123662.
198. Islam MT, Hall SA, Dutson T, et al. Endothelial cell-specific reduction in mTOR ameliorates age-related arterial and metabolic dysfunction. Aging Cell. 2024;23:e14040.
199. Moiseeva O, Deschênes-Simard X, St-Germain E, et al. Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation. Aging Cell. 2013;12:489-98.
200. Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446-56.
201. Suda M, Paul KH, Tripathi U, Minamino T, Tchkonia T, Kirkland JL. Targeting Cell senescence and senolytics: novel interventions for age-related endocrine dysfunction. Endocr Rev. 2024;45:655-75.
202. Freeberg KA, Udovich CC, Martens CR, Seals DR, Craighead DH. Dietary supplementation with NAD+-boosting compounds in humans: current knowledge and future directions. J Gerontol A Biol Sci Med Sci. 2023;78:2435-48.
203. Henderson JD, Quigley SNZ, Chachra SS, Conlon N, Ford D. The use of a systems approach to increase NAD+ in human participants. NPJ Aging. 2024;10:7.
204. Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010;53:2646-55.
205. Gil N, Goldberg R, Neuman T, et al. Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes. 2012;61:208-16.
206. Ikonomidis I, Pavlidis G, Lambadiari V, et al. Endothelial glycocalyx and microvascular perfusion are associated with carotid intima-media thickness and impaired myocardial deformation in psoriatic disease. J Hum Hypertens. 2022;36:1113-20.
207. González LDM, Romero-Orjuela SP, Rabeya FJ, Del Castillo V, Echeverri D. Age and vascular aging: an unexplored frontier. Front Cardiovasc Med. 2023;10:1278795.
208. Sánchez-Cabo F, Fuster V, Silla-Castro JC, et al. Subclinical atherosclerosis and accelerated epigenetic age mediated by inflammation: a multi-omics study. Eur Heart J. 2023;44:2698-709.
209. Tomusiak A, Floro A, Tiwari R, et al. Development of an epigenetic clock resistant to changes in immune cell composition. Commun Biol. 2024;7:934.
